

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Share

Tweet

Linkedin

Email

Print

[Home](#) | [Back to Product Details](#)

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N210251

Product 001
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE (BIKTARVY) TABLET EQ 50MG BASE;200MG;EQ 25MG BASE

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
001	7390791	01/07/2025	DS	DP			02/26/2018
001	7390791*PED	07/07/2025					
001	8754065	08/15/2032	DS	DP	U-257		02/26/2018
001	8754065*PED	02/15/2033					
001	9216996	12/19/2033	DS	DP			02/26/2018
001	9296769	08/15/2032	DS	DP	U-257		02/26/2018
001	9296769*PED	02/15/2033					
001	9708342	06/19/2035	DS	DP			02/26/2018
001	9732092	12/19/2033	DS	DP			02/26/2018
001	10385067	06/19/2035			U-257		08/30/2019
001	10548846	11/08/2036		DP			02/28/2020
001	11744802	11/08/2036		DP			10/04/2023

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
001	ODE-256	06/18/2026
001	I-942	02/23/2027
001	M-305	04/24/2027
001	ODE-468	02/23/2031